Merck, Ridgeback to advance outpatient COVID-19 therapy to phase III trial

By The Science Advisory Board staff writers

April 15, 2021 -- Merck and Ridgeback Biotherapeutics have announced they will move forward with a phase III trial of EIDD-2801/MK-4482 (molnupiravir), an oral antiviral developed for outpatient treatment of people suffering from COVID-19.

The phase II trial included 302 participants randomized to receive molnupiravir in 200 mg, 400 mg, or 800 mg doses as compared to a placebo twice daily for five days. The primary end point was the percentage of participants hospitalized or who died compared to the placebo arm during the period from randomization through day 29.

No deaths were considered drug-related by the investigators, and there were no drug-related adverse events that led to discontinuation in participants who received molnupiravir, the companies wrote in a statement.

Additionally, based on results from the same study, the companies will not proceed with a phase III trial to study molnupiravir among inpatients with COVID-19. Data indicated that molnupiravir is unlikely to demonstrate a clinical benefit for this group, who generally had a longer duration of symptoms prior to study entry, according to the release.

Merck plans to start enrolling patients by late April or early May with the goal of submitting the treatment for emergency use authorization by the second half of 2021.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here